On this page
A decentralized clinical trial is a study in which participants complete some or all trial activities outside a centralized research facility, at home, at a local clinic, or through remote visits, rather than traveling to a dedicated research site for every visit.
- Between 45.6% and 52.2% of advanced cancer patients would need to drive more than 60 minutes one way to access a traditional clinical trial site, making decentralized trials essential for reaching geographically dispersed populations [F1, F2, F3].
- Decentralized trials achieve 89% retention compared to 60% for traditional trials, reducing dropout bias and wasted enrollment resources [F4, F5].
- Decentralized trials increase representation of underrepresented groups: Asian participation rose to 20.9% versus 14.2%, indigenous representation nearly quadrupled to 1.9% versus 0.5%, and women's participation reached 55.7% versus 49.0% [F8, F9, F10, F11].
- A decentralized study with 500 participants using wearable devices and mobile apps may involve 3 to 5 different vendors, and a single vendor lacking proper security can expose the entire dataset [F12, F18].
- The FDA issued final decentralized trial guidance in September 2024, providing recommendations but not legal requirements, and removed burdensome documentation mandates to encourage adoption [F15, F16, F17].
Clinical trials have historically required participants to travel to a dedicated research site for every study visit, every lab draw, every device check. For patients with advanced cancer, rare diseases, or mobility constraints, that travel burden often means they never enroll at all. A decentralized clinical trial removes that requirement by bringing the trial to the participant: testing happens at home or at a local clinic, with remote monitoring and digital tools replacing the centralized site visit.
This is not a marginal adjustment to trial design. It is a structural shift in how drug and device sponsors collect evidence. The model changes who can participate, how long participants stay enrolled, and what data collection looks like. It also introduces new problems: managing data across multiple vendors, ensuring security when participants use their own devices, and coordinating care with local providers who have no prior relationship with the trial. Understanding decentralized trials means understanding both what they enable and what they require.
What a decentralized clinical trial is
A decentralized clinical trial is a study in which participants complete some or all trial activities outside a centralized research facility. Instead of traveling to a dedicated site, participants may take study medication at home, use a wearable device to record vital signs or activity data, complete questionnaires through a mobile app, or visit a nearby clinic or pharmacy for blood draws or other procedures. A study coordinator or nurse may call or video-conference with the participant rather than meeting in person. Local healthcare providers, a patient's own physician, a nearby urgent care clinic, a community pharmacy, may perform study-related services instead of a trial-site staff member.
The defining feature is not that all activities happen at home. It is that the trial is no longer anchored to a single physical location where participants must appear. Testing is distributed across the participant's geography and integrated into their existing healthcare routine.
How decentralized clinical trials differ from traditional site-based trials
A traditional clinical trial operates from a centralized research site. Participants travel to that site for enrollment, baseline assessments, study drug dispensing, follow-up visits, and final assessments. All procedures happen in the same facility. The site staff, nurses, coordinators, physicians, conduct every study-related activity. The participant's own doctor is typically not involved in the trial.
A decentralized trial distributes those activities. Some or all happen outside the dedicated research facility. The participant may never visit a trial site at all. Instead, a nurse calls weekly to check on symptoms. A wearable device sends data automatically to the trial database. A local pharmacy dispenses the study drug. The participant's own physician reviews lab results. This distribution means the trial depends on technology to connect the participant, the sponsor, the local providers, and the data systems, infrastructure that a traditional site-based trial does not require.
The practical consequence is that decentralized trials can reach people whom traditional trials cannot. Geographic distance is no longer a barrier to entry.
The two operational models: fully remote and hybrid
Decentralized trials are not a single design. They exist on a spectrum from fully remote to mostly site-based with some remote elements. Understanding where a trial falls on that spectrum is essential to understanding what it actually demands of participants and sponsors.
Fully remote model
In a fully remote decentralized trial, participants engage with the study entirely from home using digital tools. They complete assessments through mobile apps, receive shipments of study materials or investigational products, and conduct video visits with study staff rather than traveling to a site. Wearable devices and home-based equipment collect biometric data continuously. This model eliminates geographic barriers entirely, allowing enrollment from anywhere with internet access. Participants avoid travel time, scheduling conflicts around clinic hours, and the burden of repeated site visits. The fully remote approach works best for trials where in-person procedures are not medically necessary and where reliable remote monitoring can capture the data needed.
Hybrid model
A hybrid decentralized trial blends remote participation with selective in-person visits. Participants might complete routine check-ins and data collection at home via app or wearable, then travel to a site only for procedures that require hands-on assessment or specimen collection. Some visits happen with local healthcare providers near the participant's home rather than at a central trial site. This flexibility lets sponsors retain the rigor of direct clinical observation for critical measurements while reducing participant burden for routine monitoring. Hybrid trials accommodate studies where certain endpoints demand physical examination or invasive procedures, while other data collection can happen remotely. The model trades off some of the geographic accessibility of fully remote trials for the ability to include studies with more complex clinical requirements.
Why decentralized trials matter to drug and device development
Decentralized trials solve a fundamental problem in clinical research: the geographic mismatch between where trials are conducted and where patients live. A 2015 study of cancer patients found that 45.6% of patients with metastatic breast cancer, 50.2% with prostate cancer, and 52.2% with colorectal cancer would need to drive more than 60 minutes one way to access a clinical trial site. For patients with advanced disease, fatigue, or limited mobility, that distance is often insurmountable. Many never enroll. Those who do enroll may drop out because the travel burden becomes unsustainable.
Decentralized design removes that barrier. By bringing the trial to the participant, it expands the pool of eligible participants, increases the likelihood that enrolled participants will complete the study, and captures data from populations that traditional trials systematically exclude. This matters to sponsors because a larger, more representative trial population produces evidence that applies more broadly to the patients who will actually use the drug or device. It also matters to regulators and clinicians because evidence drawn from a diverse population is more trustworthy than evidence from a narrow geographic or demographic slice.
The real advantages of decentralized trials
The concrete benefits of decentralized trials are measurable and specific. Retention is the clearest one. In a National Center for Biotechnology Information study, retention rates were 89% for the decentralized model and only 60% for the traditional model [F4, F5]. In a low back pain trial, 89% of enrolled patients completed the decentralized arm compared to 60% in the conventional arm [F6, F7]. That difference is not trivial. A trial that loses 40% of its participants introduces bias, those who drop out may differ systematically from those who stay, and wastes the resources spent enrolling and assessing people who do not complete the study.
Decentralized trials also increase diversity. An analysis of 69 clinical trials showed that 20.9% of participants identified as Asian when decentralized components were deployed compared to only 14.2% when no solution was used [F8, F9]. Proportional representation of indigenous communities (American Indian and Alaska Native) was nearly quadruple: 1.9% versus 0.5%. Participation of women in decentralized trials was significantly higher, 55.7% versus 49.0%. These differences reflect the simple fact that removing geographic barriers allows people who live far from research centers to participate. Rural populations, communities with limited transportation, and underrepresented groups are more likely to live outside major medical centers. Decentralized design reaches them.
An IQVIA analysis found that sponsors can achieve faster, less expensive, and more engaging trials using decentralized protocols. Faster enrollment because the participant pool is larger. Less expensive because the sponsor does not need to build and staff multiple research sites. More engaging because participants interact with the trial on their own terms rather than on the site's schedule.
The obstacles that limit decentralized trial adoption
Decentralized trials are not a simple upgrade to traditional design. They introduce real obstacles that sponsors and regulators must solve before adoption becomes routine.
The first is regulatory uncertainty. In September 2024, the FDA issued final guidance on decentralized clinical trials titled Conducting Clinical Trials with Decentralized Elements. The guidance is not legally enforceable but provides recommendations for sponsors, investigators, and other stakeholders involved with implementing decentralized elements. Before this guidance existed, sponsors had little clarity on what the FDA would accept. Even now, sponsors must interpret how the guidance applies to their specific trial design. Different therapeutic areas and trial phases may require different approaches, and sponsors must navigate that ambiguity.
The second is operational complexity. A decentralized study with 500 participants using a wearable device and mobile app could involve 3 to 5 different vendors. Each vendor manages a piece of the infrastructure: the wearable device manufacturer, the mobile app developer, the data management system, the electronic consent platform, the pharmacy that dispenses study drug. Coordinating across vendors, ensuring data flows correctly between systems, and maintaining data quality becomes exponentially harder as the number of vendors increases. If even one vendor lacks proper encryption or access controls, the entire dataset could be exposed.
The third is clinical oversight. A traditional trial site has a single investigator who knows all participants and can make clinical judgments in real time. A decentralized trial distributes participants across local providers who have no prior relationship with the trial and may not be trained in the study protocol. Ensuring that these local providers follow the protocol correctly, respond appropriately to adverse events, and maintain the same standard of care across all sites is harder than oversight at a centralized facility.
The fourth is participant engagement. Remote monitoring requires participants to use digital tools, mobile apps, wearable devices, web portals, consistently and correctly. Participants who are elderly, have limited digital literacy, or lack reliable internet access may struggle. A participant who stops using the app or loses the wearable device generates incomplete data and may drop out of the trial.
These obstacles are not insurmountable, but they are real. They explain why decentralized trials are growing but have not replaced traditional site-based trials entirely.
The technology infrastructure decentralized trials require
Decentralized trials depend on technology that traditional site-based trials do not need. The infrastructure includes several layers.
Remote data collection tools capture information from participants at home. Wearable devices record vital signs, activity, or disease-specific measurements continuously. Mobile apps prompt participants to complete questionnaires, record symptoms, report medication adherence, or submit photos or other data. Web portals allow participants to view their data, communicate with study staff, or complete informed consent electronically. These tools must be user-friendly enough that participants without technical training can use them reliably.
Data management systems integrate data from multiple sources, wearables, apps, local labs, local pharmacies, participant-reported outcomes, into a single database. The system must validate data quality, flag missing or inconsistent entries, and alert study staff to potential problems. It must also comply with health privacy regulations and maintain audit trails showing who accessed what data and when.
Communication platforms enable remote interactions between participants and study staff. Video conferencing tools allow nurses to conduct virtual study visits. Messaging systems allow participants to ask questions or report problems. Phone systems route calls to the appropriate study coordinator.
Electronic consent platforms allow participants to review the informed consent document, ask questions, and provide consent digitally rather than signing a paper form at a site visit.
Integration with existing healthcare systems allows the trial to exchange information with participants' own doctors and local providers. This requires interfaces with electronic health records, pharmacy systems, and lab reporting systems, each with its own technical requirements and security standards.
Managing this infrastructure requires expertise that not all sponsors possess. Many sponsor organizations partner with specialized vendors or contract research organizations that have built decentralized trial platforms. That adds cost and complexity but allows sponsors to focus on the science rather than the technology.
How decentralized trials connect to broader clinical research trends
Decentralized trials are one part of a broader shift in how clinical research is conducted. They reflect a move toward patient-centered trial design, organizing trials around the participant's needs and constraints rather than asking participants to organize their lives around the trial.
They also reflect the maturation of digital health technology. Wearable devices, mobile apps, and remote monitoring have become mainstream consumer products. Clinical trials are adapting these tools for research use, which means the underlying technology is improving and becoming cheaper. As digital health tools become more reliable and more widely used, decentralized trials become more feasible.
Decentralized trials also align with a broader emphasis on trial diversity and inclusion. Regulatory agencies and funding organizations increasingly expect trials to enroll representative populations. Traditional site-based trials have systematically excluded people who live far from research centers, people with limited transportation, and people whose work or caregiving responsibilities make frequent site visits impossible. Decentralized design is one tool for reaching these populations.
An analysis of 1370 decentralized trials from ClinicalTrials.gov was conducted to explore key characteristics and development of the U.S.-registered DCT landscape. Sponsors are experimenting with decentralized designs for serious diseases and complex interventions. As experience accumulates and best practices emerge, decentralized trials will likely become a standard option rather than an exception. The FDA guidance issued in September 2024 reflects this shift: the agency is signaling that decentralized elements are acceptable and expected to grow.
Do this automatically
When a traditional trial requires participants to visit a centralized site for enrollment, baseline assessments, drug dispensing, and multiple follow-up visits, the cumulative burden of travel time, scheduling coordination, and site staff management across hundreds of participants creates substantial operational overhead. Decentralized and hybrid models distribute these activities across remote digital tools and selective in-person touchpoints, reducing the manual coordination required at each step. Healthcare research reads ClinicalTrials.gov records, regulatory filings, and published literature directly, and cites each claim to the record it came from, across as many subjects as you need, with Mimir attaching a citation to every figure. It will not predict a trial's outcome or advise on anyone's treatment. Those decisions stay with clinicians and regulators, and deliberately so. Every plan includes it, including the free one.
Start your first report and run it on something you already know well.
This article is general information about healthcare and life-sciences topics. It is not medical advice, diagnosis, or treatment guidance, and it is not a substitute for a qualified professional. Any treatment decision should be discussed with a clinician.
